Von Willebrand Disease Epidemiology Forecast 2021-2030 – Focus on Algeria, Egypt, Saudi Arabia, South Africa and United Arab Emirates – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Von Willebrand Disease – Epidemiology Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘Von Willebrand disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Von Willebrand disease epidemiology in the G5, i.e., Algeria, Egypt, Saudi Arabia, South Africa and United Arab Emirates.

Epidemiology Perspective

This section encompassing Von Willebrand disease epidemiology provides insights about historical and current patient pool and forecasted trend for every G5 countries. The Von Willebrand disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in G5. This segment covers the epidemiology data in the Algeria, Egypt, Saudi Arabia, South Africa, and the United Arab Emirates from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation

The Von Willebrand disease epidemiology covered in the report provides historical as well as forecasted Von Willebrand disease epidemiology scenario in the G5 covering Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates from 2017 to 2030.

The report also provides the epidemiology trends observed in the G5 countries during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Von Willebrand disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Von Willebrand disease report and model provide an overview of the global trends of Von Willebrand disease in the G5 countries (G5: Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates).
• The report provides insight into the historical and forecasted patient pool of Von Willebrand disease in G5 country covering Algeria, Egypt, Saudi Arabia, South Africa and the United Arab Emirates.
• The report helps recognize the growth opportunities in the G5 concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Von Willebrand disease.
• The report provides the segmentation of the Von Willebrand disease epidemiology.

Report Highlights

• 11-year Forecast of Von Willebrand disease Epidemiology
• G5 Coverage
• Diagnosed Prevalent cases of Von Willebrand disease
• Type-specific Cases of Von Willebrand disease
• Prevalence of Von Willebrand disease by Age
• Gender-specific Cases of Von Willebrand disease

Key Questions Answered

• What will be the growth opportunities in the G5 concerning the patient population pertaining to Von Willebrand disease?
• What are the key findings pertaining to the Von Willebrand disease epidemiology across G5 countries and which country will have the highest number of patients during the forecast period (2017-2030)?
• What would be the total number of patients of Von Willebrand disease across the G5 during the forecast period (2017-2030)?
• Among the G5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
• At what CAGR the patient population is expected to grow in G5 during the forecast period (2017-2030)?
• What is the disease risk, burden and unmet needs of Von Willebrand disease?
• What are the currently available treatments of Von Willebrand disease?

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Key Topics Covered:

1 Key Insights

2 Executive Summary of VWD

3 Von Willebrand disease prevalent pool Overview at a Glance

3.1 Prevalent pool (%) Distribution of Von Willebrand disease in 2020

3.2 Prevalent pool (%) Distribution of Von Willebrand disease in 2030

4 Overview and Background

4.1 Introduction

4.2 Etiology

4.3 Symptoms

4.4 Von Willebrand Gene and Protein

4.5 Classification and pathogenesis of Von Willebrand Disease

4.6 Diagnosis

4.7 Diagnosis guidelines

4.7.1 Saudi Arabia Diagnosis Guidelines

5 Epidemiology and Patient Population

5.1 Key Findings

6 G5 Epidemiology

6.1 Assumption and rationale

6.2 Total Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in G5

6.3 Algeria

6.3.1 Total Diagnosed Prevalent Cases of Von Willebrand disease (VWD) in Algeria

6.3.2 Gender-specific cases of Von Willebrand Disease (VWD) in Algeria

6.3.3 Age-specific cases of Von Willebrand Disease in Algeria

6.3.4 Type-specific cases of Von Willebrand disease in Algeria

6.4 Egypt

6.5 Saudi Arabia

6.6 South Africa

6.7 United Arab Emirates

7 Treatment

7.1 Treatment Guidelines

7.1.1 Treatment Guidelines of VWD in Saudi Arabia

8 Unmet Needs

9 Organizations

10 Case Study

10.1 Endodontic Management of a von Willebrand’s Disease Patient: A Case Report with a Short Review

10.2 Combination of Acquired von Willebrand Syndrome (AVWS) and Glanzmann Thrombasthenia in Monoclonal Gammopathy of Uncertain Significance (MGUS): A Case Report

10.3 A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm

11 KOL Views

12 Patient Journey

13 SWOT Analysis for VWD

14 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/z0tgmc

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900